JSR Corporation has acquired Crown Bioscience for more than $405m – the company’s largest investment to date as it turns its attention towards preclinical support for biopharma, says Life Sciences president.
Only eight of the top 40 CROs are Privacy Shield Framework-certified, says Science Exchange CEO as the company continues to rack up partnerships with pharma companies looking to streamline outsourcing efforts and mitigate risk.
Avista Capital Partners has signed an agreement to acquire United BioSource (UBC), adding another pharmaceutical service provider to the firm’s list of current and historical investments.
Avantor, Inc. has completed its previously announced acquisition of VWR Corporation to create a global provider of “discovery-to-delivery” solutions, says CEO.
Peregrine Pharmaceuticals was a biotech company – now, the company is transitioning to a pure-play contract development and manufacturing organization (CDMO) as it sells off its R&D assets.
IntelGenx Corp has granted Chemo Group an exclusive worldwide license to commercialize several products – moving the company into the novel drug delivery market.
Lonza has agreed to buy US capsule manufacturer Capsugel for $5.5bn (€5.2bn) in cash in an acquisition the Swiss firm says will expand its drug delivery business and enable savings of CHF100m a year by 2019.
Alcami has announced its first to market Protect Your Brand™ offering, which it said will support companies looking to implement a backup supply option.
The new report indicates that the US CMO market is poised for significant growth and urges international companies to enter the market – or be left behind.
With more than 90% of revenue coming from pharma and biotech companies outside the top 25, CRO SynteractHCR is seeing more growth stemming from an influx of funding to smaller biotech companies, CEO Wendel Barr told us on the third day of the 51st annual...
Chicago-based Rottendorf Pharmaceuticals, a top 20 contract development and manufacturing organization (CDMO), has signed three formulation development projects and two commercial transfer projects with multiple top pharma and biotech companies in the...
Parexel’s future course may depend on the outlook of competing CROs (contract research organizations), a couple of which could potentially go public in the near future, Ingo Bank, SVP and CFO of Parexel, said Wednesday at the Baird 2014 Healthcare Conference.
All change at biopharmas this week, as we reveal the industry movers at four biologics firms. Plus, which company is making board hires after a $52m private placement?
Granules India has outlined plans to buy drug intermediate and API maker Auctus Pharma, set up an actives R&D site and announced its intention to wind up its ‘shell’ operation in Singapore.
Saltigo has won a manufacturing contract with Daiichi Sankyo under it which it will provide custom synthesis services for one of the Japanese drugmaker’s pipeline candidates.
Onco Therapies Limited (OTL), a division of Aglia, a wholly owned subsidiary of Strides Arcolab Limited, has been given the go ahead from Europe for its Oral Dosage Oncology facility.
Pharma’s increasing collaboration and budget cuts have made hosted software more attractive to companies, according to Symyx which has made its lab notebook available on this platform.
Reaxa will set up an Indian subsidiary to manage supply chain, commercial scale production and application development for its growing number of customers in the country.
ViRexx, Aesica, Velcura Therapeutics, Helix BioPharma and Avalon
Pharmaceuticals have all had people on the move in the world of
pharmaceutical manufacturing.
Filter maker Pall Corporation has announced its plan to invest
about $50m (€63.5m) to expand its life sciences manufacturing
operations in Puerto Rico and take advantage the island's low tax
regime.
India is suddenly a safer place to research and manufacture
pharmaceuticals, thanks to legal reform, raised manufacturing
standards and reduced bureaucracy. But risk still lurks in the
loopholes and protectionism.
Degussa is streamlining its organization and decreasing the number
of business units from 20 to 17, in order to compete in the global
markets and be in a better position to exploit growth
opportunities.
Drug delivery specialists, Inyx has announced the acquisition of
Celltech Manufacturing Services from biopharmaceutical company UCB
for €27.5 million (€22.3 million). The acquisition adds to Inyx's
recently established operating...
LION bioscience has said it plans to cut its headcount by at least
50 per cent as part of a new restructuring drive, with most cuts
being felt at the company's facilities in Heidelberg, Germany.
Drug development company Jerini has transferred its peptide
technologies business unit to a wholly owned subsidiary which will
continue to provide and develop peptide-based services and products
for biomedical research.
SC Biosciences is to be the exclusive distributor of sensitive
tools for drug discovery with the announcement this week that it
will distribute in vivo imaging technology in Japan for US company
Xenogen corporation.
